Proteome punished as sales fail to perk up
24th Jul 2018 08:04
(Sharecast News) - Proteome Sciences trimmed losses in the first half as the protein biomarker specialist cut costs and revenues stalled.
Read moreProteome Sciences trades in line as it consolidates lab facilities
9th Feb 2017 11:14
(ShareCast News) - Proteome Sciences provided a trading update for the 12 months to 31 December on Thursday, saying that after a strong first half, progress continued throughout the rest of the year with results in line with expectations. The AIM-traded firm said buoyed by robust sales of its TMT re
Read moreProteome Sciences plunges after highly discounted placing
31st Oct 2016 09:18
(ShareCast News) - After offering the shares at a highly discounted price before getting shareholder approval, Proteome Sciences has raised £3.3m through a placing and subscription of new shares to accelerate its strategy and meet client demand. The AIM-listed company issued the shares at 5p, a 45%
Read moreProteome Sciences shares slide as losses widen
15th Sep 2016 10:34
(ShareCast News) - Proteome Sciences released its unaudited interim results for the six months to 30 June on Thursday, with revenues to 30 June increasing 32% to £1.12m. The AIM-traded company said revenue from licences, sales and services increased 44% to £1.08m during the period, while TMT reagent
Read moreProteome raises £2.5m from placing
23rd Jun 2015 13:26
Protein biomarker company Proteome Science has placed 13.86m shares at 18p each, raising £2.5m before expenses. The proceeds will be used to increase capacity and shorten lead times ensuring the company can continue to meet the significant increase in demand for its biomarker services from a growing
Read moreProteome slides after warning on revenues
12th Nov 2014 12:00
Shares in Proteome fell sharply on Wednesday after the group warned its revenue for the current year will be lower than market expectations and "somewhat" lower than the revenues achieved in 2013. The protein biomarker group explained that it had seen a continuation of the previously flagged delay t
Read moreProteome Sciences wins $2m biomarker deal
25th Sep 2014 15:29
teerngasAIM biotech Proteome Sciences has been signed up to provide to develop diagnostic products for Alzheimer's disease group Genting TauRx Diagnostic, worth $2m in upfront and milestone payments. Proteome's biomarker services division will analyse blood samples from patients enrolled in a phase
Read moreXP Power board members reduce holdings
28th Feb 2014 16:18
XP Power's Chairman, Larry Tracey, on Thursday sold 75,000 shares in the power supply solutions manufacturer. Tracey, who has held his current role since April 2002, disposed of the shares at 1,755p a time, generating a total of £1.3m. Fellow board member James Peters, a Non-Executive Director, t
Read moreProteome edges ahead after flagging rise in revenue
7th Feb 2014 10:06
Biotech group Proteome Sciences edged ahead after it revealed it expects revenue for 2013 to show "a significant increase" over 2012 thanks to strong performance across its core activities. The firm is an expert in biomarkers, or biological markers, that can help predict the likelihood of cancer r
Read moreProteome Sciences unveils sales delays, shares fall
4th Dec 2013 10:39
Biotechnology group Proteome Sciences is facing sales delays that will push revenue from some deals into next year, hitting its shares. Proteome, which carries out research into protein and peptide biomarkers to treat neurological conditions and other illnesses such as cancer, said the timing and r
Read moreProteome Sciences to develop cancer pathway profiling assays
12th Jun 2013 11:37
AIM-listed biotech group Proteome Sciences has unveiled its largest contract to date comprising a technology agreement with Thermo Fisher Scientific, to develop advanced methods to profile changes in cancer pathways. Proteome Sciences said that the contract - which it valued at £2.1m - would prov
Read moreProteome Sciences looks ahead with confidence
18th Mar 2013 14:29
Drug developer Proteome Sciences has told investors that it expects strong revenue growth across the company's three main divisions in 2013 and said it is 'much encouraged by the prospects'. The announcement comes after the group received a positive response to the presentation of four posters tha
Read moreProteome delivers encouraging results from Alzheimers study
31st Dec 2012 10:48
Drug maker Proteome Sciences has completed the in-vivo study of its CK1D inhibitor programme in Alzheimer's disease on time, with the results showing that both of the lead compounds for CK1D demonstrated improved cognitive function. The firm said the results provide important in-vivo proof of prin
Read moreProteome Sciences narrows losses, bright outlook
28th Sep 2012 10:46
Proteomics specialist Proteome Sciences reduced half year losses and expects second half revenues to be significantly boosted as it doubles the number of biomarker tests available from PS Biomarker Services. The group expects major licences and contracts from its proprietary biomarkers and services
Read moreProteome stroke test could save thousands from brain damage
18th Sep 2012 10:57
Medical technology group Proteome Sciences has released details of a study into a blood test which could reduce brain damage in thousands of stroke victims. The group has been collaborating with researchers at the University of Geneva to produce the test which can tell how long ago a stroke actuall
Read more